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ABSTRACT

BACKGROUND: Cancer patients are more prone to drug interactions as multiple medications
are administered concomitantly along with cytotoxic agents in addition with drugs targeted to
treat underlying comorbidities, and these are poorly evaluated. In the challenging field of
cancer where the number of patients diagnosed increases in a geometric manner, the difficulties
faced by healthcare professionals to treat the patients poses a great deal of arduous task in
designing an optimum therapeutic regimen. This study addresses the current dilemma and
suggests to bring about a resolution to the existing problem.

OBJECTIVES: The primary objective of this study is to characterize, in a group of lung
cancer patients, the frequency of clinically pertinent interactions involving anticancer drugs
along with prescribed drugs and other anti-tumour agents. Secondary objective involves
identifying the types of drugs mainly involved, their severity and adverse consequences, and
discussing its management.

METHODOLOGY: The study was conducted in Kasturba Hospital, Manipal, a tertiary care
setting. 197 patients receiving chemotherapy fulfilled the inclusion criteria. Drug interactions
were recorded from two sources, Micromedex Healthcare services and Epocrates (free
version), and categorised as pharmacokinetic and pharmacodynamic interactions. Severity and
significance of the drug interactions were assessed as per the two sources. A descriptive
analysis of the data collected was carried out using Microsoft Excel Spreadsheet.

RESULTS: Among 196 patients receiving chemotherapy, 555 drug interactions were found in
185 patients using both, Micromedex and Epocrates. Based on mechanism of action, 76% of
the interactions were found be to pharmacodynamic, 20% of the interactions fell under the
pharmacokinetic category, and 4% of the interactions were found to be occurring via both
mechanisms, pharmacokinetic as well as pharmacodynamic. 112 drug interactions were found
in Micromedex alone while 589 interactions were found using only Epocrates.
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CONCLUSION: Numerous drug- drug interactions were found in patients admitted to
Kasturba Hospital, Manipal. This suggests a strong need for collaboration between the
oncologists and clinical pharmacists, who with their clinical knowledge can help minimise the
number of drug- drug interactions by conducting medication therapy reviews regularly, and
help resolve the current issue in the future.
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INTRODUCTION

Cancer is a group of disease, involving uncontrolled multiplication and spreading of abnormal
forms of one’s own body cells.
Chemotherapy is a treatment option for majority of cancers. In chemotherapy, drugs are
targeted to destroy cancer cells. In olden days, cancers were treated with a single drug. But
nowadays, a combination of drugs is given to overcome the cancer cell heterogeneity and
development of drug resistant cells to kill the total tumour cells.
Since cancer chemotherapy involves administration of more than one drug, the incidence of
drug–drug interactions (DDIs) prevail, and majority of these interactions result in adverse drug
reactions (ADRs). 20–30% of all ADRs have been reported to be caused by DDIs in the general
population.(1) A meta- analysis has showed that 7% of the hospitalisations may be drug- related.
DDIs in about 4% of the cancer patients have also reported to cause death.(2)
Risk factors leading to drug interactions include the use of drugs that are significantly
influenced by inhibition or induction of drug metabolism (Eg: TKIs- Tyrosine Kinase
Inhibitors), the use of drugs that have a considerable potential to inhibit or induce drug
metabolism (antifungal medications), and the use of drugs with narrow therapeutic window as
in the case of warfarin. Risk factors may also be patient-specific involving older age, renal or
hepatic dysfunction, and the use of multiple prescribed medications. Generally, cancer patients
receive diversiform drugs concomitantly, consisting of cytotoxic agents, supportive care
agents, targeted agents and hormonal agents to treat underlying conditions. This leads to an
increase in the plausibility of DDIs, where simultaneous administration of two drugs alters the
pharmacological effect of the other drug.(3) Population analysis have shown that older patients
receive multiple drugs due to increased comorbidities. Additionally, the risk of drug-drug
interactions is augmented by altered age leading to exacerbating changes in the overall
physiology causing comorbidities; eg, changes in the gastric mucosal layer resulting in altered
absorption and hepatic and renal impairment, thereby altering excretion.(4)
DDIs occurring in a clinical setting can be majorly differentiated as pharmaceutical,
pharmacokinetic, and pharmacodynamic interactions.(4) Pharmaceutical DDIs occur when
there is a manifestation of two physically or chemically incompatible compounds. Example:
Thiol mesna leading to the inactivation of cisplatin. When the two are combined together for
infusion, it will result in the formation of a mesna- platinum adduct. A pharmacokinetic
4

interaction occurs when the absorption, distribution, metabolism, or excretion of one drug is
precipitated by another drug. These types of interactions generally involve factors influencing
absorption, or due to effects on the cytochrome P-450 isoenzymes. When medications are
administered intravenously, there is 100% bioavailability as it bypasses hepatic metabolism.
Pharmacodynamic DDIs occur when there is a direct influence of drugs on each other leading
to a modification in its pharmacologic effect, that may be a synergistic effect, additive effect,
or antagonistic effect, and are usually a result of overlapping mechanisms of action or
toxicities.(4) Pharmacodynamic interactions may be both, harmful (ototoxicity due to cisplatin
and furosemide(5)) or beneficial (enhanced pharmacologic effects of gemcitabine with
cisplatin).
A major treatment advance for many cancers has been the introduction of effective oral
therapies, as it is desired to improve efficacy while curtailing toxic effects. Patients usually
prefer prescription of oral anticancer therapies rather than infusion as the former reduces
hospitalisation costs and also aids in saving. However, since most of the anticancer drugs are
metabolised by CYP enzymes(4) and due to chronic use, oral anticancer agents pose a potential
risk for DDIs than injectable agents.(6,7) Meagre collaboration between general practitioners,
medical oncologists, and pharmacists also leads to potential DDIs frequently going
unnoticed.(8)
Over a considerable period, it has been recognized that there is progressive increase in the use
of proton pump inhibitors (PPIs) and histamine H2-receptor antagonists (H2RAs) to mitigate
gastroesophageal reflux disease (GERD) and indigestion intrinsic to malignancy and anticancer
therapy. These drugs have the capacity to reduce drug exposure of particular molecular targeted
oral chemotherapeutic agents, as they are weakly basic in nature and exhibit pH-dependent
solubility. (9, 10) Tyrosine kinase inhibitors (TKIs) constitute a remarkable fraction of all oral
anticancer medications and are mostly given continuously on a regular basis rather than
cyclically. Pharmacokinetic drug interactions are affected by CYP inducers and inhibitors and
since most TKIs are substrates of the CYP3A4 enzyme, pharmacokinetic interactions among
TKIs are prevalent.(11)
One of the most significant reasons for morbidity and mortality in cancer patients involves
DDIs, since the toxic effects of the drugs get amplified, thereby reducing their therapeutic
potency. In oncology, DDIs are of major concern due to the narrow therapeutic index that
chemotherapy medications pose. Therefore, an inappreciable rise or decline in cytotoxic
5

activity of a drug due to an interaction by various medications can result in alterations in their
pharmacokinetic (PK) and pharmacodynamic (PD) activity.
Considering DDIs, pharmacists can play a vital role in minimising their occurrences.
Identification and handling of DDIs is crucial in order to provide safe and efficacious anticancer treatment.
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AIMS AND OBJECTIVES

Aim: To evaluate the effectiveness of the drugs used for lung cancer therapy in Kasturba
Hospital, Manipal.

Objectives:
i.

Primary Objective: To characterize the prevalence of clinically pertinent interactions
involving anticancer drugs along with the prescribed drugs and other anticancer agents,
in a cohort of lung cancer patients.

ii.

Secondary Objective: To determine the types and classes of drugs mainly involved,
their severity and ADRs, and discuss its management.
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REVIEW OF LITERATURE
Cancer patients are at a greater risk of experiencing drug-drug interactions and it has been the
objective of several studies conducted. A few instances have been discussed below with regard
to pharmacodynamic and pharmacokinetic interactions.

1) PHARMACODYNAMIC DRUG INTERACTIONS
Pharmacodynamic DDIs occur when there is a direct influence of pharmacological effect of
one drug by another drug when given in combination. Here, one drug may have an additive,
synergistic, or antagonistic effect on another. These interactions are particularly important to
be identified when chemotherapy drugs that are nephrotoxic are administered together. Drugs
possessing an additive effect can result in renal failure that may be mild-to-moderate.(12)
Whereas, when the effect of one drug is impeded by another, the effects of these drugs are
antagonistic.
Often, a PD interaction is desired if mutually potentiating or synergistic effects are used for
therapeutic advantage, e.g., using different drug classes for pain control. Two drugs exhibiting
synergistic activity will require lower doses when given in combination. Combinations of
gemcitabine with cisplatin and pemetrexed respectively, have particularly shown favourable
results in regard to their synergistic properties.(13,14) The mechanisms that contribute to this
effect include nucleotide-pool modulation, cellular DNA repair capacity, and drug metabolism.
Commonly co-prescribed drug classes having the highest risk of QT-prolongation include antiinfectives, anti-emetics, anti-depressants, anti-psychotics, high-dose loperamide, and pain
killers such as tramadol. Likelihood of QT prolongation may also be caused by drugs inhibiting
the metabolism of oral anticancer therapies. There are reports suggesting mild QTc
prolongation with paclitaxel.(15,16) However, it appears to have only a low risk of incidence
(1%- 5%).
Studies have reported that Erlotinib increases INR when used concomitantly with warfarin.
Hence, patients need to be closely monitored along with necessary dose adjustments.(17)
It has been found that there is a probable decline in renal function in consequence to continued
pemetrexed administration when combined with NSAIDs.(18) In patients receiving the
combined chemotherapy of carboplatin and pemetrexed along with NSAIDs, drug interactions
10

between pemetrexed and NSAIDs have reported to cause severe hematologic toxicities which
may be induced by inhibiting the tubular secretion of pemetrexed.(19) Therefore, it is imperative
to take required safety measures against such adverse side effects while using these
combinations, by conducting periodic examinations.
Shan F et al. performed a meta-analysis in patients with advanced non-squamous non- small
cell lung cancer (NSCLC) to assess the effect of the maintenance therapy involving the
combination of pemetrexed and bevacizumab. Patients showed to develop a statistically
increased risk of grade 3 and 4 adverse experiences.(20) Bevacizumab or pemetrexed alone, as
a single-agent maintenance therapy was found to be efficacious, but due to insufficient
evidences to support benefit of survival and high toxicity, this combination is not
recommended.(21)
Combination of cisplatin and vinorelbine was found to be effective in treating advanced
NSCLC. However, in a study conducted by Hotta K et al, grade 4 neutropenia was recorded in
86% of all cycles and grade 3 leukopenia was noted in 57% of the cycles, while reaction at the
injection site and grade 3 infection were reported to be the most severe non- haematological
toxicity symptoms.(22)
Findings of a study conducted by Lee EH et al. displayed that continuous high dose steroid
(20 mg prednisolone for ≥ 3 weeks) therapy and concurrent chemo- radiation therapy were risk
factors for Pneumocystis Jirovecii Pneumonia (PJP),a serious infection caused in patients with
lung cancer and was associated with a very poor prognosis.(23)

2) PHARMACOKINETIC DRUG INTERACTIONS
Pharmacokinetic drug interactions arise as a result of four basic principles: absorption,
distribution, metabolism, and elimination. The interaction is considered clinically significant if
it causes toxicity or alters therapeutic response of a drug.
a. Absorption
Absorption of various oral chemotherapy agents is often influenced by multiple factors,
including acid-suppressive agents. Ultimately, these factors impact the solubility and
bioavailability of chemotherapy agents. Drugs exhibiting low oral bioavailability are generally
affected often, while those with high bioavailability are rarely affected. For example, a study
11

which evaluated the effect of omeprazole on a single dose of erlotinib, showed to reduce the
Cmax and AUC of erlotinib by about 61% and 46%,(24) respectively while in another study, AUC
and Cmax of erlotinib were reduced by ranitidine by 33% and 54% respectively.(25) It also
resulted in a reduction of 44% and 70% for the AUC and Cmax of gefitinib, respectively.(26)
Drug transporters present in the gut epithelium may also be responsible for impaired drug
absorption. For example, P-glycoprotein (P-gp) significantly hinders the uptake of numerous
oral anticancer drugs, one of them including paclitaxel. On administering ciclosporin, a Pglycoprotein inhibitor, it blocked P-gp activity, thereby increasing the bioavailability of
paclitaxel and attaining appropriate plasma drug concentrations.(27-31)
b. Distribution
Specific drug characteristics such as high protein-binding (>90%) and narrow therapeutic
index, increase the likelihood of altered distribution. Major factors affecting the distribution of
drugs include the ability of the drug to bind to proteins like albumin, lipoproteins,
immunoglobulins, erythrocytes, and alpha1-acid glycoprotein. Highly protein bound anticancer
drugs like paclitaxel and etoposide have shown to provoke protein displacement of warfarin,
another protein- bound drug, consequently increasing the patient's INR.(32)
c. Metabolism
Metabolism primarily occurs in the liver involving the cytochrome P450 enzymes. These
enzymes are accountable for majority of the phase I process of the oxidative metabolism of
drugs. Out of the 100 isoenzymes, most of the anti-cancer drugs are mainly metabolized by the
following 6 enzymes: CYP3A4, CYP2C9, CYP1A2, CYP2E1, CYP2D6, and CYP2C19, out
of which the first three isoenzymes are most clinically significant. The CYP3A4 isoenzyme is
known to metabolize about 50% of all medications.
Drugs such as cyclophosphamide; paclitaxel and docetaxel; nilotinib, erlotinib and a few other
oral chemotherapy agents are partially metabolized by the CYP3A4 isoenzyme. When
combined with other CYP3A4 substrates, inhibitors, or inducers it can alter their activity. There
are various drugs which competitively inhibit or induce cytochrome P450 enzyme–binding
sites. This can alter the metabolism of mainly oral chemotherapy agents, thereby altering their
efficacy and safety.(33)
Careful assessment of drug interactions is also recommended when a patient starts treatment
with oral anticancer agents. Antifungals such as itraconazole, voriconazole, posaconazole, and
12

ketoconazole are strong inhibitors of CYP3A4, which interact with a large majority of TKIs.
Erlotinib, an EGFR TKI, is metabolized largely by CYP3A4 and by CYP1A2 to an
insignificant extent. When administered with ketoconazole, it resulted in elevated erlotinib
concentrations. On the other hand, when it is given along with CYP3A4 inducers such as
rifampin, it demonstrated to decrease erlotinib's concentrations and effectiveness by causing a
60%- 70% reduction in AUC.(17) Thus, dose adjustment is essential for the co-prescribed oral
anticancer agents that are major CYP3A4 substrates.
In addition to PD interactions, a number of PK interactions also occur between oral anticancer
therapies and direct oral anticoagulants. Metabolism of all direct oral anticoagulants occurs via
either the CYP3A4 isoenzyme or P-gp transporter, or both. Concurrent use of
chemotherapeutic agents and warfarin causes inhibition of the CYP450 class of enzymes
resulting in drug interactions. Warfarin is a major CYP2C9 substrate as well as a minor
substrate of the CYP3A4, CYP2C19, and CYP1A2 isoenzymes. Patients taking gemcitabine
and warfarin concurrently, too have displayed a significant rise in INR which could be due to
either a decline in the synthesis of clotting factors, or due to diminished warfarin metabolism
which may be a result of CYP450 inhibition.(35) Thus, patients receiving anticoagulation
therapy with warfarin should regularly check their INR and dose adjustments must be done
accordingly.

When erlotinib is concurrently administered with phenytoin, it can cause decreased erlotinib
concentrations and efficacy due to induced hepatic metabolism. Combination of erlotinib and
phenytoin has also resulted in elevated serum phenytoin concentration leading to phenytoin
toxicity.(34)

d. Excretion
Most of the anticancer drugs are eliminated after undergoing metabolism. Chemotherapy
agents such as methotrexate and platinum compounds are excreted primarily by the kidneys.
Cisplatin influences the renal clearance of topotecan(36), resulting in enhanced toxicity such as
myelosuppression.(37)
Christopher J. S. found that coadministration of ibuprofen and pemetrexed significantly
reduced the systemic clearance of pemetrexed.(38)
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Rodman et al. (1992) found that when etoposide was administered with the anticonvulsants
such as phenobarbital or phenytoin to paediatric patients with cancer, etoposide clearance was
increased to 170% of that of etoposide alone.(39)

Oral Anti-cancer Therapy
There is a remarkable increase in the number of studies that examine the pharmacokinetic
variability between parenteral and oral administration.
Acid suppression (AS) by antacids, H2RAs, and PPIs disrupt absorption of oral anticancer
therapies by suppressing the secretion of acid by the parietal cells and raising the intragastric
pH from ~1.2 to ~4. Most of the TKIs including gefitinib and erlotinib, manifest weak basic
properties and pH-dependent solubility.(9, 10, 40) They are more ionic in an acidic environment
and more soluble, since they get optimally absorbed. Therefore, due to the hypochlorhydic
conditions brought about by these agents, equilibrium tends to shift from the ionized to the
non-ionized form, thereby reducing their absorption. This results in diminished exposure to the
drug and as a consequence, affects the efficacy of gefitinib and erlotinib.
One such study was conducted retrospectively in NSCLC patients who were treated with
gefitinib and erlotinib.(8) Among 269 patients, 57 patients (21.2%) used acid-lowering therapy.
Use of these drugs was associated with reduced overall survival (OS). Among patients with
brain metastases, the OS was shorter with utilisation of acid-lowering therapy at 11.8 months
compared to 16.3 months among non- users.

14
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METHODOLOGY

Study subjects
The study was conducted at Kasturba Medical Hospital, Manipal, and included all patients with
lung cancer admitted to Shirdi Sai Baba Cancer Hospital and Research Centre, between January
2015 and July 2019.
Ethical Clearance: The ethical approval was obtained from the Institutional Ethics Committee
of Kasturba Hospital, Manipal.
Inclusion criteria: Lung cancer patients with a solid tumour and those who received
chemotherapy fulfilled the inclusion criteria. Secondly, drug interactions were taken into
account only if the anti-cancer drugs and co-medications were administered concomitantly.
Exclusion criteria: Patients who were discharged beyond the physician’s request.
Data collection
For every patient under inclusion, all drugs administered concomitantly to the patients along
with the chemotherapy regimen, i.e., the co-medications, including multivitamins were
identified and recorded. Data was gathered from the medical records department, and included
the following demographics: age of the patient, sex, cancer stage, type of lung cancer, smoking
status, co-morbidities, chemotherapy regimen and other co-medications administered,
including discharge medications.
DDIs were checked for each anti-tumour drug taken by every patient. Anti-cancer drugs were
taken into consideration irrespective of the class of drug, days of administration, and route of
administration [intravenous (I.V.) and oral]. Two drug interaction sources were utilised to
identify the interactions between the anticancer drugs and non- anticancer drugs: IBM
Micromedex Drug Reference, and Epocrates (free version).(41, 42)
In Micromedex, DIs are classified into five categories of severity: contraindicated, major,
moderate, minor and unknown. Only the first three categories were chosen for this study
because interactions of minor severity lack clinical significance. Epocrates classifies DIs in
terms of their management, namely- contraindicated, avoid use or use alternative, monitor or
modify treatment, and caution advised. All of the four categories were taken into consideration
and none were dismissed.
16

All interactions found in atleast one of the two sources were recorded. DDIs were classified
into two based on their mechanism of actions, either as PK or PD.
Statistical analyses
Data obtained were entered into Microsoft Excel Spreadsheet and a descriptive analysis was
carried out with regard to the characteristics of drug interactions. The drugs mainly involved
were identified, along with their severity and adverse consequences, as well as source(s) of
information.

17
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RESULTS
Patients: On the basis of inclusion criteria, 196 patients receiving chemotherapy were
evaluated, out of which 129 (65.8%) were males and 67 (34.2%) females, with a range of 2786 years. Among 196 patients, 3 patients underwent surgery and 57 received radiation along
with chemotherapy. The demographic characteristics of the patients are summarised in Table
1. Patients took an average of 6 co-medications. Figure 1 presents the number of chemotherapy
cycles received by the patients. In 196 patients, a total of 23 anti-cancer drugs were identified
as shown in Table 2.

50
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29

30

21
20
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Number of cycles
Figure 1. Number of chemotherapy cycles received by lung cancer patients.
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Table 1. Patient Characteristics (n= 196)
Gender
Age

BMI

Tumour stage
Metastasis

Co-morbidities3

Drugs used4

Male
Female
Mean ± SD
Range
< 60 years
≥ 60 years
Underweight
Normal
Overweight
Class I Obesity
Class II Obesity
Unknown1
Earlier than IV
IV
Bone
Brain
Neuroendocrine tumour (NET)
Spine
Others2/ Unknown
None
HTN
Diabetes
COPD
PTB
None
Oral chemotherapy
I.V. chemotherapy
Targeted therapy

129 (65.8)
67 (34.2)
58.81 ± 10.73
27- 86
100 (50.8)
97 (49.2)
36 (18.4)
90 (45.9)
42 (21.4)
4 (2)
1 (0.5)
22 (11.2)
75 (38.3)
121 (40.3)
23 (11.8)
17 (8.6)
8 (4.0)
3 (1.5)
72 (36.5)
74 (37.6)
58 (29.6)
43 (29.9)
14 (7.1)
10 (5.1)
76 (38.8)
83
316
15

Values are n (%).
1
Patient unable to stand.
2
Others include liver, kidney, adrenal, pancreatic, and cervical mets.
3
Some patients had more than 1 co-morbidity, while other insignificant comorbidities are not taken into account.
4
Some patients received more than one chemotherapy agent.
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Table 2. List of various anti-cancer agents used
Drug Class

Frequency in

Percentage

patients1

(%)

Gefitinib

80

40.8

Erlotinib

6

3.1

Crizotinib

2

1.0

Afatinib

2

1.0

Carboplatin

83

42.3

Cisplatin

59

30.1

Pemetrexed

50

25.5

Gemcitabine

36

18.4

Paclitaxel

28

14.3

Docetaxel

7

3.6

Vincristine

2

1.0

Vinorelbine

2

1.0

Anthracyclines

Doxorubicin

2

1.0

Nitrogen Mustard

Cyclophosphamide

2

1.0

Monoclonal Antibodies

Nivolumab

7

3.6

Bevacizumab

5

2.6

Denosumab

1

0.5

Nimotuzumab

1

0.5

Cetuximab

1

0.5

Etoposide

33

16.8

Topotecan

1

0.5

Everolimus

1

0.5

Bleomycin

1

0.5

EGFR inhibitors

Platinum compounds

Anti- Metabolites

Anti- Mitotic agents

Vinca Alkaloids

Topoisomerase Inhibitors

Miscellaneous
1

Drug Name

Some patients received more than one chemotherapy agent.
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Drug- Drug Interactions: Figure 2 presents the chemotherapy medications with atleast one
potential DDI identified using Micromedex and Epocrates. Among 196 eligible patients, a total
of 595 drug interactions were found in 185 patients using both, Micromedex and Epocrates.
Upon categorising them based on mechanism of action, 76% of the interactions were found be
to pharmacodynamic, 20% of the interactions fell under the pharmacokinetic category, and 4%
of the interactions were found to be occurring via both mechanisms, pharmacokinetic as well
as pharmacodynamic (Figure 3). 112 drug interactions were found using only Micromedex,
and 589 interactions were found in Epocrates, alone (Figure 4). Characteristics of these DI are
presented in Table 3. In terms of severity, there were 107 ‘major’ DDIs, equating to 18% of
the total number (n= 595).

120

113

Number of drug interactions

101

100

Micromedex

100
87

Epocrates

80
68

60

40

37

34

30
22

20
5

8

4 4

8
2

1

2

3

0

0

0

8

0

6 6

0

0

4

1

5

1 1

0

Drugs

Figure 2. Frequency of DDIs for each chemotherapeutic agent that had atleast one
identified DDI.
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DRUG INTERACTION MECHANISM
4%

22%

74%

Pharmacokinetic

Pharmacodynamic

Both

Figure 3. Classification of drug interactions based on their mechanism, commonly
obtained from both sources, Micromedex and Epocrates.

MICROMEDEX

EPOCRATES

10%

3%

22%

8%

82%

Pharmacokinetic
Both

Pharmacodynamic

75%

Pharmacokinetic

Pharmacodynamic

Both

Figure 4. Drug interactions and their mechanisms obtained from two different sources,
Micromedex and Epocrates
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Table 3. Characteristics of Interactions (n= 595)
Drugs involved

Significance

Adverse
Consequences

Management

Sources of
information

Between an anticancer agent and prescribed drug
Between two anticancer agents
Between an anticancer agent and Miscellaneous Products1
According to Micromedex (n= 112)
Contraindicated2
Major interactions3
Moderate interactions4
According to Epocrates (n= 589)
Avoid/Use alternative
Monitor/Modify treatment
Caution advised
Increased toxicity of anticancer agent
Increased toxicity of co-medication
Increased toxicity of both agents
Decreased efficacy of anticancer agent
Additive effects
Increased toxicity of anticancer agent + Additive effect
Increased toxicity of co-medication + Additive effect
Decreased efficacy of anticancer agent + Additive effect
Antagonistic effect
Monitor treatment
Avoid use
Alter dosage
Use alternative drug
Separate administration by 2 hours
Separate administration by 6 hours
Administer 24 hours before/ after myelosuppressive chemo
Separate administration by 12 hours
Nothing suggested
Interactions found in both sources
Interactions found only in Micromedex
Interactions found only in Epocrates

474 (79.6)
69 (11.6)
52 (8.7)
1
107
4
128
333
128
6
26
75
91
293
86
10
2
6
310
6
3
58
1
19
6
64
128
106
112
589

Values are n (%).
1
Miscellaneous Products: Calcium Carbonate, Filgrastim and Zoledronic acid
2
Contraindicated: The drugs are contraindicated for concurrent use.
3
Major: The interaction may be life threatening and/or require medical intervention to minimize
or prevent serious adverse effect.
4
Moderate: The interaction may result in exacerbation of the patient’s condition and/or require an
alteration in therapy.
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The most common identified DDI was that of Gefitinib + PPIs (which includes pantoprazole,
esomeprazole and rabeprazole) (11.5%), followed by Carboplatin + Dexamethasone (11.3%)
and Cisplatin + Dexamethasone (9.5%). The most frequently occurring interactions are
depicted in Figure 5. The remaining interactions had fewer instances (<6%).
It was found that out of 196 patients, 43 patients (21.4%) experienced 1 drug interaction, 51
patients (26%) experienced 2 drug interactions, and 38 patients (19.4%) had 3 interactions,
while the remaining had more than 3 drug- drug interactions.

Gefitinib + PPIs

64

Carboplatin + Dexamethasone

63

Interactions

Cisplatin + Dexamethasone

53

Pemetrexed + Carboplatin

33

Gemcitabine + Dexamethasone

33

Etoposide + Dexamethasone

32

Paclitaxel + Dexamethasone

28

Gefitinib + Tramadol

22

Cisplatin + Mannitol

21

Pemetrexed + Cisplatin

20
0

20

40

60

80

Number of drug interactions

Figure 5. Frequency of the Top 10 Drug- Drug Interactions found in our study group of
lung cancer patients.
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95, 48%
134, 68%

CYP Inhibitors

CYP Inducers

Figure 6. Frequency of lung cancer patients receiving atleast one CYP Inhibitor and
CYP Inducer in our study group (n= 196). Some patients received more than one CYP
inducer/ inhibitor.

Given below is the list of inducers and inhibitors of the CYP450 system of isoenzymes along
with their substrates (Table 4). The strength of enzyme activity is categorised as weak,
moderate, and strong. It was found that 95 (48.5%) patients were prescribed atleast one CYP
isoenzyme inducer while 134 (68.4%) patients took atleast one CYP isoenzyme inhibitor, as
shown above in Figure 6. The medications used in both groups include those prescribed as
supportive care agents and to treat the clinically significant associated comorbidities. The CYP
isoenzyme inducers and inhibitors most commonly taken by patients in our study group
included antacids, anti- emetics, anti- hypertensives, anti-fungals, and corticosteroids.
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Table 4. List of CYP 450 isoenzymes in our study group: Substrates, Inhibitors and Inducers
CYP3A4
Pantoprazole
Gefitinib
Crizotinib
Erlotinib
Etoposide
Paclitaxel
Docetaxel
Doxorubicin
Cyclophosphamide
Vinorelbine
Everolimus
Vincristine

CYP3A5
Gefitinib
Crizotinib
Etoposide
Paclitaxel
Docetaxel
Cyclophosphamide
Vincristine

CYP3A4
Acetaminophen +
Dexamethasone +
Ranitidine +
Mirtazepine +
Olanzapine +
Octreotide +
Clindamycin ++
Fluconazole ++
Aprepitant ++
Isoniazid ++
Milnacipran ++
Itraconazole +++
Efavirenz +++
Loperamide +++

CYP3A5
Fluconazole +
Amlodipine +

CYP3A4
Warfarin +
Clobazam +
Dexamethasone ++/+++
Rifampicin +++
Rifaximin +++

CYP3A5
Budesonide ++
Dexamethasone ++

CYP Substrates
CYP2C8
Domperidone
Erlotinib
Atorvastatin
Paclitaxel

CYP2C9
Cyclophosphamide
CYP2C19
Pantoprazole
Cyclophosphamide
CYP Inhibitors
CYP2C8
Erlotinib +
Amoxicillin +
Amitriptyline ++
Ondansetron ++

CYP2D6
Tramadol
Phenytoin
Codeine
Domperidone
Diphenhydramine
Dextromethorphan
Chlorpheniramine
Tapentadol
Acetaminophen
Loperamide
Gefitinib
Olanzapine

CYP2D6
Metoclopramide
Ondansetron
Atenolol
Nebivolol
Theophyline
Zolpidem
Tamsulosin
Amiodarone
Quetiapine
Sildenafil
Formoterol

CYP2E1
Etoposide
CYP1A2
Pemetrexed

CYP2E1
Etoricoxib +

CYP2C19
Aprepitant +
Etoricoxib +

CYP2D6
Gefitinib +
Amitriptyline +
Etoricoxib +
Amiodarone +
Isoniazid +
Rabeprazole +
Verapamil +
Vinorelbine +
Clotrimazole ++
Clobazam ++
Metoprolol ++

CYP Inducers
CYP2C8/ 2C9/ 2C19
Nil

CYP2D6
Nil

CYP2E1
Etoricoxib +

CYP2C9
Aprepitant +

Weak: +; Moderate: ++; Strong: +++
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Prevalence of treatment with the CYP 450 inducers and inhibitors is shown in Table 5. As
depicted, CYP3A4 was found to be the majorly involved CYP isoenzymes.
As mentioned earlier, one of the most common pharmacokinetic interactions involved gefitinib
and pantoprazole. Though the frequency of interaction seemed to be higher, considering the
enzymes involved in the CYP pathway, gefitinib appears to be a CYP 3A4 inhibitor of
pantoprazole of an unestablished strength. However, being a major pharmacokinetic
interaction, it is recommended that more studies be conducted to establish its strength so as to
aid in clinical decision making.

Table 5. Prevalence of Treatment with CYP isoenzymes Inducers and Inhibitors
(n= 196)
CYP
Isoenzyme

No. treated with CYP

No. treated with CYP

Inducer

Inhibitor

Weak

Moderate

Strong Weak

Moderate

Strong

3A4

5

78

83

114

53

7

3A5

˟

88

3

25

1

˟

2C8

˟

˟

˟

5

3

˟

2C9

˟

˟

˟

2

˟

˟

2C19

˟

˟

˟

2

˟

˟

2D6

˟

˟

˟

69

5

˟

2E1

3

˟

˟

3

˟

˟

˟ Not applicable
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DISCUSSION
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DISCUSSION

In order to present the data in a qualitative manner, the common DDIs are summarised in Table
6 along with the mechanism of the interacting drug and their resulting effects.
It was found that 185 patients out of 196 patients undergoing chemotherapy were prone to
experiencing atleast one potential DDI. Polypharmacy was observed among patients with, as
well as without metastatic tumours. Many patients were found to be taking medications having
a significant potential for pharmacodynamic DDIs as well as CYP isoenzyme- mediated
pharmacokinetic DDIs.
Upon classifying the DDIs based on the mechanism of action in Micromedex and Epocrates,
there exists an evident difference in the type of interactions found between the two drug
sources. As shown in Figure 4, Micromedex describes DDIs mainly based on pharmacokinetic
interactions, whereas Epocrates describes them mainly based on pharmacodynamic
interactions. However, both sources are user- friendly and are accurate in terms of their
sensitivity and specificity.
Oral drug delivery appears to possess unique considerations, and thus it is essential for
oncologists to understand the potential DDIs it may relate to. Interactions involving oral
anticancer drugs can result in intensifying the toxic profile of the drug or a substantial decrease
in efficacy if not managed properly. The oncologist and clinical pharmacist must jointly
manage these patients by conducting an open discussion with the patients. These drugs should
be prescribed only after thoroughly reviewing the concomitantly administered medications, to
address the potential DDIs, if any. Patients must also be counselled on proper administration
of such medications to ensure optimal absorption and minimize toxicity.
In order to avoid interactions between PPIs and TKIs, PPIs must be preferably switched to
H2RAs, or the interaction can also be minimised by administering H2RAs at night,
approximately 12 hours apart from the drug, i.e., erlotinib and gefitinib. Moreover, over-thecounter acid- lowering agents such as antacids, if needed, can be administered, provided that a
dosing interval of 2 hours before or after the administration of these oral chemotherapeutic
agents is maintained.
Certain TKIs can result in profound toxicity if administered with strong inhibitors of CYP3A4.
On the other hand, strong inducers of CYP3A4 could significantly decrease the activity of the
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TKIs. Thus, in cases where concurrent administration of erlotinib, a TKI and a strong CYP3A4
inducer is required, an alteration in the dose by 50 mg daily must be deemed necessary, whereas
when given along with CYP3A4 inhibitors, dose must be augmented by 50 mg, and patients
must be monitored carefully.(17)
Stopping gastric acid suppressants such as PPIs can be difficult, however in a study conducted
by Van Leeuwen et al, researchers reported that it may be possible to neutralise the decreased
absorption of TKIs by using an acidic beverage such as cola during drug administration. When
tested with erlotinib, it showed to increase the bioavailability of erlotinib by approximately
40%, and may help minimise the associated drug interaction.(43).
In patients initiating oral chemotherapeutic drugs that may be likely to increase vulnerability
to warfarin toxicity, INR must be carefully monitored until stabilization is attained.
Additionally, patients should also be counselled regarding the signs and symptoms of bleeding.
In addition to PPIs, several interactions were also found between gefitinib and tramadol. The
combination is known to inhibit the hepatic metabolism of tramadol, thereby preventing its
conversion into its active metabolite. This can increase the likelihood of various ADRs
including CNS depression and respiratory depression, as well as QT prolongation that could
lead to cardiac arrythmias. Periodic monitoring of RR and ECGs must be carried out.(44)
Dexamethasone, a supportive care agent for the mitigation of nausea and vomiting in anticancer
therapy, has found to be one of the most frequently administered co-medications. Among the
DDIs found in our study group, we noticed that dexamethasone was the most common
interacting co-medication. It mainly showed to interact with cytotoxic agents like carboplatin
and cisplatin. When administered concurrently, it causes an additive effect through an unknown
mechanism, thereby increasing chances of hypokalemia and serious infection. Potassium levels
in these patients must be kept under a constant check and any signs of infection must be treated
at the earliest.
Combination of cisplatin and mannitol is known to increase cisplatin levels, thereby causing
myelosuppression and nephrotoxicity. A phase II clinical trial involving cisplatin and mannitol
in patients with advanced lung cancer, led by Jager DR et.al revealed that renal toxicity was
observed in 9.9% (8 out of 81 patients) of the patients, with a peak S.Cr. (serum creatinine)
>2.5 mg/100 ml, as well as 1 death due to toxicity. Mild myelosuppression was also
observed.(45) Patients taking such combinations must be monitored for CBC, sodium levels,
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renal function, and ototoxicity. In view of reducing the risk of developing nephrotoxicity,
magnesium supplements can be administered along with cisplatin therapy.(46)
Pharmacist’s role
Proficient pharmacists can play a major role in improving patient care. As clinical pharmacists,
we can contribute by screening the medications prescribed to the patients along with the
chemotherapeutic drugs, examining the plausibility of DDIs, and managing them by closely
monitoring them, endorsing modifications in dose, or providing alternate treatment options.
This can help improve effectiveness of the anti-cancer drugs, thereby curtailing its toxicity.
Pharmacists can also counsel patients regarding the likelihood of DDIs, and advise them to
consult their oncologists or pharmacists before using any OTC acid- lowering medications.
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Table 6. Characteristics of the Commonly Interacting Drugs.
Anticancer
agent
Gefitinib

a

Interacting
Drug

Mechanism

Frequency
(n)

PPIsa

PK

64

H2RAb/
Antacidsc

PK

Warfarin

Recommendation/ Management

Source

Major- Absorption of gefitinib
decreased at higher gastric pH.

Administer gefitinib 12 hours after the
last dose or 12 hours before the next
dose of the proton pump inhibitor

Micromedex/
Epocrates

9

Major- Absorption of gefitinib
decreased at higher gastric pH.

Administer gefitinib 6 hours after or 6
hours before a H2RA or antacid

Micromedex/
Epocrates

PK/ PD

2

Moderate- May increase
prothrombin time and INR and
risk of bleeding.

Monitor for changes in prothrombin
time (PT) or INR, during first 2 weeks
following warfarin initiation. Warfarin
dose adjustment may be needed.

Micromedex/
Epocrates

Tramadol

PK

22

Hepatic metabolism inhibited;
Decreased conversion of tramadol
to active metabolite.

Use alternative or monitor RR, ECG
and withdrawal syndrome

Epocrates

Calcium
Carbonate

PK

10

Major- Absorption of gefitinib
decreased at higher gastric pH.

Separate administration by 6 hours

Micromedex/
Epocrates

Phenytoin

PK

1

Major- Induction of CYP3A4
mediated metabolism of gefitinib.

Monitor Phenytoin levels: Increase
gefitinib dose to 500 mg during and x7
days after phenytoin

Micromedex/
Epocrates

Itraconazole

PK

1

Hepatic metabolism of gefitinib is
inhibited

Caution advised

Epocrates

Rifampin

PK

1

Major- Induction of CYP3A4
mediated metabolism of gefitinib

Inc. gefitinib dose to 500 mg during
and x7 days after rifampin

Micromedex/
Epocrates

PPIs- Pantoprazole, Rabeprazole, Esomeprazole
H2RAs- Ranitidine
c
Antacids- Magnesium Hydroxide
b

Possible Mechanism and
Severity

Erlotinib

Pantoprazole

PK

4

Calcium
Carbonate

PK

1

PK/ PD

1

Crizotinib

Fluconazole

Carboplatin

Dexamethasone

PD

70

Hydrocortisone

PD

6

Formoterol/
Terbutaline
Telmisartan

PD

5

PD

7

Mannitol

PD

2

Furosemide

PD

1

Naproxen/
Ibuprofen/
Diclofenac

PD

7

Warfarin

PD

1

Major- Absorption decreased at
higher gastric pH
Major- Absorption of erlotinib
decreased at higher gastric pH

Avoid combination

Contraindicated- May result in
QT prolongation and cardiac
arrythmias- Hepatic metabolism
inhibited & Additive effects
Additive effect- Risk of
hypokalemia and serious infection

Use alternative or monitor ECG,
electrolytes

Micromedex/
Epocrates

Monitor Potassium

Epocrates

Additive effect- Risk of
hypokalemia and serious infection
Additive effect- Risk of
hypokalemia
Additive effect- Risk of infection,
myelosuppression, nephrotoxicity.
Additive effect- Risk of infection,
myelosuppression, nephrotoxicity.
Additive effect- Risk of infection,
myelosuppression, nephrotoxicity
and hypokalemia
Additive effect- Risk of serious
infection, myelosuppression,
nephrotoxicity.

Monitor Potassium

Epocrates

Monitor potassium

Epocrates

Monitor CBC, renal function and
ototoxicity
Use alternative or monitor CBC, renal
function and ototoxicity
Use alternative or monitor CBC, renal
function and potassium

Epocrates

Monitor CBC, renal function and
ototoxicity

Epocrates

Major- Risk for elevated INR and
subsequent bleeding

Monitor INR and monitor for signs of
bleeding. May require warfarin doage
adjustment.

Micromedex

Separate administration by 2 hours

Micromedex/
Epocrates
Micromedex/
Epocrates

Epocrates
Epocrates
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Cisplatin

Dexamethasone

PD

61

Terbutaline

PD

3

Mannitol

PD

27

Hydrochlorothi
azide

PD

3

Naproxen/
Diclofenac

PD

8

PK/ PD

1

Warfarin

Paclitaxel

Dexamethasone

PD

29

Docetaxel

Dexamethasone

PD

6

Etoposide

Dexamethasone

PD

38

Gemcitabine

Dexamethasone

PD

33

PK/ PD

3

Warfarin

Additive effect- Risk of
hypokalemia and serious infection
Additive effect- Risk of
hypokalemia
Additive effect- Risk of infection,
myelosuppression, nephrotoxicity.
Additive effect- Risk of infection,
myelosuppression, nephrotoxicity,
hypokalemia, SIADH and
hyponatremia
Additive effect- Risk of serious
infection, myelosuppression,
nephrotoxicity, SIADH and
hyponatremia
Moderate- Increased INR
(Unknown mechanism)
Additive effect- Risk of serious
infection
Additive effect- Risk of serious
infection
Additive effect- Risk of serious
infection
Additive effect- Risk of serious
infection
Major- Increased risk of bleeding
due to reduced warfarin
metabolism and decreased hepatic
synthesis of clotting factors

Monitor Potassium

Epocrates

Monitor potassium

Epocrates

Use alternative or monitor CBC, renal
function and ototoxicity
Monitor CBC, renal function,
ototoxicity and electrolytes

Epocrates

Monitor CBC, renal function and
sodium levels

Epocrates

Monitor INR while starting and
stopping warfarin, or consider
changing the dosage of Cisplatin.
Caution advised

Micromedex

Caution advised

Epocrates

Caution advised

Epocrates

Caution advised

Epocrates

Monitor INR. May require warfarin
dose reduction.

Micromedex

Epocrates

Epocrates
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Pemetrexed

Nivolumab

Bevacizumab

Carboplatin

PD

33

Additive effect- Risk of serious
infection, myelosuppression,
nephrotoxicity and auditory
adverse effects.

Monitor CBC, renal function and
ototoxicity

Epocrates

Cisplatin

PD

20

Additive effect- Risk of serious
infection, myelosuppression,
nephrotoxicity and auditory
adverse effects.

Monitor CBC, renal function and
ototoxicity

Epocrates

Naproxen

PK/ PD

2

Monitor CBC and renal function

Micromedex/
Epocrates

Dexamethasone

PD

4

Caution advised

Epocrates

Prednisolone/
Hydrocortisone

PD

4

Major- Additive effect- Decreased
clearance of pemetrexed may
result in risk of myelosuppression,
nephrotoxicity and GI toxicity.
Additive effect- Risk of serious
infection
Additive effect- Risk of serious
infection

Caution advised

Epocrates

Dexamethasone

PD

4

Additive effect- Risk of
hypertension

Monitor BP

Epocrates
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LIMITATIONS
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LIMITATIONS

1. The study conducted was single- centered and not a multi-centre study.

2. A larger sample size would have been desired.

3. Clinical impact of DDIs were not evaluated due to the study being retrospective.

4. Cost of therapy was unaffordable to many patients as they were from a low to averageincome based category. Hence, they refused treatment and requested for discharge
against medical advice (DAMA).

5. Confounding results between the two drug databases used in the study.

6. Inexplainable comparisons between significance levels of these two databases.
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CONCLUSION
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CONCLUSION
Numerous drug- drug interactions were found in patients admitted to Kasturba Hospital,
Manipal. Physicians must be alerted of the potential adverse events that may be caused due to
these drug- drug interactions. Medication therapy review is not commonly practiced in our
hospital. This suggests a strong need for clinical pharmacists, who with their clinical
knowledge can help minimise the number of drug- drug interactions by regularly reviewing the
medication therapies. Collaboration of oncologists and clinical pharmacists can prove to
resolve the current issue.
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